Healthcare Mar 01, 2021 11:55 AM (GMT+8)
It is reported that the new price of PD-1 monoclonal antibody baizean (tirilizumab injection), which was independently developed by Baiji Shenzhou, was as low as 2180 yuan / piece (100mg) before medical insurance reimbursement, with a price drop of as much as 80%. The annual treatment cost was less than 75000 yuan, and the annual treatment burden of patients with medical insurance reimbursement indications was lower. This time, bazaar was included in the medical insurance for two indications, including for the treatment of recurrent or refractory classical Hodgkin's lymphoma (R / R CHL) and locally advanced or metastatic urothelial carcinoma (UC). Bazaar has become the only PD-1 monoclonal antibody with the medical insurance reimbursement qualification for urothelial carcinoma indications.
This text is a result of machine translation.